ImmunityBio Stock Extends A 6-Day Losing Streak To A 31% Loss
ImmunityBio (IBRX) stock is on a 6-day losing streak, down 30.7% since the run began. That erased about $2.8 billion from the company’s market value, which now stands at about $6.3 billion. The stock closed at $5.98 on Monday, November 16, 48.2% below its 52-week high of $11.55 and 202.0% above its low of $1.98.

IBRX Versus The S&P 500
Returns for IBRX and the S&P 500 over the streak and the periods around it, all ending Monday, November 16 and including dividends:
| Return Period | IBRX | S&P 500 |
|---|---|---|
| 1 Day | -0.7% | -1.9% |
| 6 Days (Current Streak) | -30.7% | 0.6% |
| 1 Month (21 Trading Days) | -34.9% | -3.1% |
| 3 Months (63 Trading Days) | -22.5% | -3.3% |
| Year To Date | 202.0% | 9.4% |
| 1 Year (252 Trading Days) | 199.0% | 11.4% |
Is This Move About ImmunityBio Or The Market?
Over the same 6 trading days, the S&P 500 returned +0.6% including dividends, so the slide is mostly ImmunityBio’s own story rather than the market’s. Over the past three months the stock is down 22.5%, a window that includes the streak; over the other 57 sessions of that window it was up 11.9%.
Is The Business As Weak As The Stock?
On the fundamentals, revenue grew 121.2% over the last twelve months, against a median of 7.9% for S&P 500 Health Care stocks; and its operating margin is -150.2%, versus a median of 17.4%. ImmunityBio does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The fundamentals give the sellers some support: an operating loss.
If the drop has you weighing an entry, resist buying on price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still hold up.
For anyone who would rather back the theme than one company, a biotech ETF like XBI holds the whole group, not just this stock. It is still a concentrated bet on one theme, which is the gap the portfolio below is built to close.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Make the next streak, in either direction, someone else’s drama.